>
$64.76 -1.5 -2.3%
Last Trade - 9:00pm
Market Cap | £2.92bn |
Enterprise Value | £2.15bn |
Revenue | £233k |
Position in Universe | 1604th / 6825 |
Industry | Market | |
---|---|---|
|
|
|
|
|
|
|
|
Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
---|---|---|---|---|---|---|---|---|---|---|
13.4 | 92.2 | 21.3 | 18.0 | 806.4 | 0.32 | 23.3 | 61.6 | -52.6% | ||
x
|
||||||||||
Profitability | ||||||||||
%
|
||||||||||
%
|
||||||||||
%
|
||||||||||
Cashflow | ||||||||||
Dividends | ||||||||||
Balance Sheet | ||||||||||
m
|
||||||||||
m
|
||||||||||
m
|
||||||||||
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing % | |||
Net Gearing % | |||
Cash / Assets % |
Liquidity (ttm) | ||
---|---|---|
Curr. Ratio | ||
Quick Ratio | ||
Interest Cov. |
Efficiency (ttm) | ||
---|---|---|
Asset Turnover | ||
Recs Turnover | ||
Stock Turnover |
Latest interim period vs. prior period | Industry | Market |
---|---|---|
|
|
|
|
|
3yr Compound Annual Growth Rate | Industry | Market |
---|---|---|
|
|
|
|
|
|
|
|
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
Last Annual | December 31st, 2020 |
Last Interim | December 31st, 2020 |
Incorporated | April 14, 1997 |
Public Since | July 28, 2000 |
No. of Shareholders: | 81 |
No. of Employees: | 363 |
Sector | Healthcare |
Industry | Biotechnology & Medical Research |
Index | Nasdaq Composite , |
Exchange | NASDAQ Global Select Market |
Shares in Issue | 60,334,648 |
Free Float | (0.0%) |
Eligible for |
✓
ISAs
✓
SIPPs
|
Address | 6154 Nancy Ridge Dr, SAN DIEGO, 92121-3223, United States |
Web | http://www.arenapharm.com/ |
Phone | +1 858 4537200 |
Contact | () |
Auditors | KPMG LLP |
As of 9:00pm, shares in Arena Pharmaceuticals Inc are trading at $64.76, giving the company a market capitalisation of £2.92bn. This share price information is delayed by 15 minutes.
Shares in Arena Pharmaceuticals Inc are currently trading at $64.76 and the price has moved by 40.15% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arena Pharmaceuticals Inc price has moved by -5.54% over the past year.
Of the analysts with advisory recommendations for Arena Pharmaceuticals Inc, there are there are currently 4 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Arena Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Arena Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:
Arena Pharmaceuticals Inc does not currently pay a dividend.
Arena Pharmaceuticals Inc does not currently pay a dividend.
Arena Pharmaceuticals Inc does not currently pay a dividend.
To buy shares in Arena Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Arena Pharmaceuticals Inc are currently trading at $64.76, giving the company a market capitalisation of £2.92bn.
Here are the trading details for Arena Pharmaceuticals Inc:
Based on an overall assessment of its quality, value and momentum, Arena Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Arena Pharmaceuticals Inc are currently priced at $64.76. At that level they are trading at 44.94% discount to the analyst consensus target price of 0.00.
Analysts covering Arena Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -8.175 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arena Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -30.75%. At the current price of $64.76, shares in Arena Pharmaceuticals Inc are trading at -8.46% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Arena Pharmaceuticals Inc.
Arena Pharmaceuticals Inc's management team is headed by:
Here are the top five shareholders of Arena Pharmaceuticals Inc based on the size of their shareholding: